Citadel Advisors’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Citadel Advisors’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-65,190	Closed	-$78.2K	–	14845
2026 Q1	$78.2K	Sell	65,190 -13,093	-17%	-$17.6K	﹤0.01%	12191
2025 Q4	$129K	Sell	78,283 -48,593	-38%	-$61.9K	﹤0.01%	11438
2025 Q3	$199K	Buy	126,876 +103,336	+439%	+$188K	﹤0.01%	11271
2025 Q2	$30.4K	Buy	+23,540	New	+$33.4K	﹤0.01%	11973
2021 Q3	–	Sell	-185,587	Closed	-$184K	–	14655
2021 Q2	$184K	Sell	185,587 -338	-0.2%	-$334	﹤0.01%	12256
2021 Q1	$205K	Buy	+185,925	New	+$336K	﹤0.01%	11648

Other funds holding TLSIW

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.57% 1-Year Est. Return

FBCM

Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Citadel Advisors's TLSIW Position: Q2 2026 in Review

Citadel Advisors sold out of TriSalus Life Sciences Warrant (TLSIW) in Q2 2026, closing a stake of 65,190 shares — an estimated $78.2K sold.

Citadel Advisors first reported a position in TLSIW in Q1 2021 and held it in 6 quarters. The position peaked at $205K in Q1 2021. 5 funds tracked by Wall St. Rank hold TLSIW as of Q2 2026.

Citadel Advisors reported no remaining TriSalus Life Sciences Warrant position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 65,190 TriSalus Life Sciences Warrant shares in Q2 2026, an estimated $78.2K.
Citadel Advisors first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and held it in 6 quarters.
Citadel Advisors's TriSalus Life Sciences Warrant position peaked at $205K in Q1 2021.
5 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.